Vir Biotechnology (VIR) News
NASDAQ: VIRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VIR news summary
We found 13 recent headlines mentioning Vir Biotechnology (VIR): 1 in the past week and 10 in the past 30 days, most often from Nasdaq, Seeking Alpha, Business Wire. VIR is making an outsized move today, down 5.41% at $8.39, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Vir Biotechnology, Inc. Prices 15,000,000 Share Public Offering of Common Stock at $10.00 Per Share", was published by Nasdaq on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Vir Biotechnology headlines
- Vir Biotechnology, Inc. Prices 15,000,000 Share Public Offering of Common Stock at $10.00 Per ShareOn November 12, 2026, Vir Biotechnology, Inc. entered into an underwriting agreement with Leerink Partners LLC, Morgan Stanley & Co. LLC and Evercore Group L.L.C., as representatives of the several…Nasdaq
- Why is Vir Biotechnology stock tumbling today?Investing.com
- Vir Biotechnology dips 15%, prices $150M equity raise $10 per shareSeeking Alpha
- Vir Biotechnology, Inc. Reports 44% Response Rate in Phase 3 ECLIPSE 1 Trial and Week 96 SOLSTICE DataVir Biotechnology, Inc. announced topline results from its pivotal Phase 3 ECLIPSE 1 clinical trial evaluating monthly subcutaneous administration of the combination regimen of elebsiran and…Nasdaq
- Vir Biotechnology shares rise on hepatitis D therapy dataSeeking Alpha
- Vir Biotechnology reports positive hepatitis results, early signs of possible cureSeeking Alpha
- Vir Bio (VIR) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Vir Biotechnology, Inc. Reports Third Quarter 2026 Financial ResultsVir Biotechnology, Inc. reported its financial results for the third quarter ended September 30, 2026. The company reported a net loss of $96.3 million, or $0.57 per share, basic and diluted,…Nasdaq
- Vir Biotechnology Non-GAAP EPS of -$0.57 beats by $0.18Seeking Alpha
- Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsSAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2026. “We are…Business Wire
- Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial ResultsSAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, November 4 to provide a…Business Wire
- Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.NasdaqGILD, AZN, BMY, VIR
- Vir Biotechnology Partners With Gilead On Next-Generation Cancer Immunotherapy Programs(RTTNews) - Vir Biotechnology, Inc. (VIR) has entered into a multi-program collaboration and license agreement with Gilead Sciences (GILD) to discover and develop three novel PRO-XTEN dual-masked…NasdaqGILD, VIR